FDAnews Joins WIRB-Copernicus Group

7/20/17

WIRB-Copernicus Group (WCG), the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research, announced today that it has acquired FDAnews, which provides global regulatory information for executives in the clinical research, biopharmaceutical and medical device industries.

FDAnews joins clinical trial publishing leader CenterWatch to create a powerful new resource for the life science community. FDAnews/CenterWatch provides a suite of well-respected newsletters, books, databases, market intelligence reports, conferences and webinars, including Drug Industry Daily, CenterWatch Monthly, the Clinical Trials Data Library, the Medical Device Quality Congress and the FDA Inspections Summit.

"We are delighted to welcome the accomplished team from FDAnews to our family of companies and excited to see what the combination of FDAnews and CenterWatch will produce for our industry," said Donald A. Deieso, PhD, chairman and CEO of WCG.

"We have long prided ourselves on providing thought leadership and information solutions to the clinical trials community and look forward to extending our offerings to other segments of the biopharmaceutical and medical device ecosystem," said Deieso. "Our clients will benefit from real-time access to regulatory actions, industry developments and other critical issues that affect life sciences organizations."

"We are very excited to join CenterWatch and the family of WCG companies and look forward to what we will collectively deliver to our clients," said Cynthia Carter, president of FDAnews/CenterWatch. "My team has long admired CenterWatch products and we share WCG's mission of providing high-quality products and services to the industry."

Serving the industry for 50 years, WCG is the trusted partner of biopharmaceutical companies, CROs, institutions and central research sites, and has overseen research conducted by 90 percent of the country's FDA-regulated investigators. Comprised of the largest and most highly accredited institutional review boards (IRBs) in the world, WCG's chief focus is on finding ways to accelerate the clinical research process and protect study volunteers.

Like the other WCG companies, FDAnews/CenterWatch will operate independently as a publishing division within the group and will be respectively located in Falls Church, Virginia and Boston, Massachusetts. WCG will support the new company as it continues to expand with access to capital, expertise and corporate operational support.

About WIRB-Copernicus Group

WIRB-Copernicus Group (WCG) is the world's leading provider of solutions to measurably improve the quality and efficiency of clinical research. The industry's first clinical services organization (CSO), WCG enables biopharmaceutical companies, CROs and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human subject protections. For more information, please visit www.wcgclinical.com or follow us on Twitter@WCGClinical.

About FDAnews

Founded in 1972 by David Swit, FDAnews is a pioneer in the creation of focused information for the biopharmaceutical and medical device industries. Over the last 45 years it has expanded to include high-quality conferences and webinars and continues to provide valuable, highly curated information for the life science community. For more information, please visit www.fdanews.com.

About CenterWatch

Founded in 1994 by Ken Getz, CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals, ranging from sponsors and CROs to investigative sites. CenterWatch provides proprietary data and information analysis on clinical trials and industry trends through a variety of well-respected newsletters and books, including CenterWatch Monthly and the Clinical Trials Data Library. For more information, please visit www.centerwatch.com.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.